Founder and CEO of ChemPass. Previously, Greg was CEO and CTO at ComInnex, Inc. (2012 – 2015) where he co-founded the company’s chemistry business and helped grow the operation to 40+ people, Prior, he was the Managing Director and Director of Chemistry at AMRI Hungary for 4 years (2008 – 2012).
Between 2004 and 2008 he worked as a Senior Research Fellow at Merck & Co. in Rahway NJ supervising Merck’s Target Validation Chemistry group where he was responsible for developing Merck’s fragment-based lead discovery platform and its application to lead discovery programs. During 1998 – 2004 Greg held various managing positions at NeoGenesis Pharmaceuticals including Director of Library Development and Hit-to-Lead Optimization. He did his postdoctoral studies with Professor Garland Marshall in the Center of Drug Design at Washington University at St. Louis. Overall, Greg spent 15 years in the United States where his groups contributed to the development of a Safety Assessment Candidate and a Preclinical Candidate.
Director of Chemistry
Co-founder and Head of Chemistry at ChemPass. Previously, Laszlo was the CEO at InFarmatik Kft. and InFarmatik, Inc. where he founded the company, initiated the chemistry business and instrument development then grew the operation to 20+ people. Prior, he was VP and Director of Chemistry at ComGenex Hungary for 6 years (1992 – 1998). Between 1982 and 1992 he worked as a Research Fellow at Gedeon Richter Chemical Works’ process R&D group.
Meanwhile in the period between 2008 and 2014 Laszlo was co-founder and co-CEO of MediMass a medical device company with a core mass spectrometry technology (IKnife) for on line tissue analysis in surgery rooms. The company was acquired by Waters Corp. in 2014.
Laszlo obtained a doctor univ. degree in organic chemistry in 1994, and a M.S. (1982) and a B.S. (1980) degree in medicinal chemistry at the Budapest University of Technology and Economics.
Head of Software Development
Gabor is the Head of Software Development at ChemPass. Previously, he was the Head of IT and Software Development at ComCIX, Inc. (2011 – 2016) where he developed and commercialized an eNotebook-IT platform for the chemistry and pharmaceutical industries.
Prior, Gabor had a similar role as the Head of IT and Software Development at AMRI Hungary (2006 – 2011) and the IT Manager and Director at ComGenex (1997 – 2006) where his team developed a highly integrated production platform for chemistry R&D and library production.
He obtained his engineer degree from the Technical University of Budapest in 1997.
Business Development Consultant
In the US he was a research group leader at Neurex Corporation (1994-1998) and Laszlo did his postdoc at the Wistar Institute in Philadelphia and at Brandeis University in Waltham, MA.
He is a Vice President of the Hungarian Association for Innovation and a Member of the Board of the Hungarian Biotechnology Association.
Stevan W Djuric, PhD
Discovery Chemistry and Technology Consulting LLC,
Dr Stevan Djuric was, until retirement in February 2019, head of the global AbbVie Medicinal Chemistry Leadership Team at AbbVie and Vice President of the Discovery Chemistry and Technology organization. The group’s efforts were focused on initiatives in the areas of high throughput synthesis and purification, hit to lead chemistry, chemical biology and new MS based analytical technologies. In 2015 he was named a Distinguished Research Fellow. During his tenure at Abbott and AbbVie Laboratories, Dr Djuric was a Project Leader for groups in the Immunoscience, Metabolic Disease, and Antiinfective areas. Several of these programs have advanced compounds into clinical development and to the market including Abbott’s proprietary rapamycin analog, Zotarolimus, currently licensed to Medtronics for use on their vascular stents, marketed in the United States and Europe. Dr Djuric has over 180 scientific publications, presentations and patents/applications pending. He has also given over 40 invited lectures at universities and national meetings. He is a member of several Editorial Advisory Boards including the Journal of Medicinal Chemistry and ACS Medicinal Chemistry Letters. In addition, he holds an Adjunct Professorship in the Department of Medicinal Chemistry at the University of Kansas and one at High Point University in North Carolina.
György M. Keserű, PhD
Scientific Advisor, Group Head, Medicinal Chemistry Research Group at Research Centre for Natural Sciences
In 2007 he was appointed as the Head of Discovery Chemistry at Gedeon Richter. During his tenure he was involved in the discovery of 10 clinical candidates (41 patent applications) that entered into clinical development in neurological and psychiatric indications. He also contributed to the discovery of the antipsychotic Vraylar® (US)/ Reagila® (EU) that was approved by the US FDA in 2015 and European authorities in 2017. The drug has been on the US market since 2016 and available to European patients since 2018. After his departure from Gedeon Richter he served as a Director General of the Research Centre for Natural Sciences (RCNS) at the Hungarian Academy of Sciences. He has played a significant role in the development of physicochemical profiling in drug discovery, the concept of compound quality and the improvement of optimization strategies in medicinal chemistry. His achievements have been acknowledged by the George A Olah Award, the Prous Institute Overton, and Meyer Award of the European Federation of Medicinal Chemistry.
In 2016 he was elected as a Fellow (FRSC) of the Royal Society of Chemistry. Since 2015 he has been a full professor at the Budapest University of Technology and Economics, and he has been heading the Medicinal Chemistry Research Group at RCNS. In 2019 he was elected to be a member of the Hungarian Academy of Sciences. His research interests include medicinal chemistry and drug design. He has published over 200 papers and more than 10 books and book chapters.